TLDR
- ARK Invest acquired approximately $19.4M in CoreWeave shares following a sharp 19% decline triggered by Q4 earnings results
- The fund’s most substantial transaction involved purchasing $23.2M of Kratos Defense & Security Solutions stock
- Teradyne position reduced by $12.9M, extending ARK’s recent pattern of downsizing this holding
- Despite Rocket Lab exceeding earnings forecasts, ARK decreased its stake as shares dropped roughly 5%
- Additional portfolio adjustments included divesting Roku and initiating a position in Generate Biomedicines
On Friday, February 27, Cathie Wood’s ARK Invest executed a series of strategic portfolio adjustments spanning technology, defense, and biotechnology sectors. The trading activity featured fresh acquisitions alongside continued position trimming.
Kratos Defense & Security Solutions emerged as the day’s most significant acquisition. ARK accumulated 252,169 shares valued at $23.2 million. The company specializes in unmanned aerial systems and autonomous defense technology, aligning perfectly with ARK’s investment focus on robotics and automation innovation.
The portfolio’s second-largest addition involved CoreWeave, a provider of AI-focused cloud infrastructure services. ARK secured 198,980 shares totaling approximately $19.4 million, distributed between its ARKK and ARKW exchange-traded funds.
CoreWeave, Inc. Class A Common Stock, CRWV
ARK’s CoreWeave acquisition occurred during a challenging trading session that saw the stock tumble 19%. The sharp decline followed fourth-quarter financial results that revealed robust revenue growth but simultaneously disclosed expanded losses and higher-than-anticipated capital expenditures.
By purchasing shares during the downturn, ARK appears to interpret the market reaction as temporary volatility rather than fundamental business deterioration. CoreWeave operates in the AI computing infrastructure space, a sector experiencing substantial demand acceleration.
CoreWeave maintains a Moderate Buy rating among Wall Street analysts. With eleven Buy recommendations and eight Hold ratings, the consensus price target of $114.18 suggests potential appreciation of approximately 43.5% from current trading levels.
ARK Reduces Teradyne and Rocket Lab
Regarding divestitures, ARK liquidated 38,773 Teradyne shares worth $12.9 million across several exchange-traded funds. Teradyne produces semiconductor testing systems and industrial automation solutions. This transaction continues ARK’s recent pattern of systematically reducing its Teradyne exposure.
ARK also divested 46,921 Rocket Lab shares valued at approximately $3.4 million. The aerospace company had recently announced quarterly performance that surpassed both earnings and revenue projections, yet shares declined roughly 5% during Friday’s trading session.
While Rocket Lab showcased impressive launch cadence and expanding order backlog, the company’s inaugural Neutron rocket launch timeline was postponed to late 2026, potentially contributing to investor disappointment.
Other Moves Across Biotech and Tech
ARK divested 46,389 Roku shares worth $4.3 million from its ARKK exchange-traded fund. The rationale behind this reduction was not publicly disclosed.
Within biotechnology investments, ARK acquired 459,525 Generate Biomedicines shares valued at $7.4 million through its ARKG fund. Simultaneously, the firm sold 39,423 Ionis Pharmaceuticals shares for $3.2 million.
ARK liquidated 10,590 Deere & Co shares for $6.6 million and reduced its Guardant Health position by 27,334 shares worth $2.7 million.
Additional minor adjustments included reducing PagerDuty holdings by 205,211 shares for $1.5 million and acquiring 14,097 Brera Holdings shares for approximately $15,600.
The combined CoreWeave and Kratos acquisitions represented ARK’s most substantial trading activity on February 27, exceeding $42 million in aggregate investment.
